KXAN

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as ...
NBC4 Columbus

Caris Life Sciences and Flatiron Health Partner to Vastly Increase Access to Most Comprehensive Molecular Testing Available

Partnership broadens precision medicine access at the point of care with seamless ordering and receipt of Caris molecular profiling results directly in patient records via the OncoEMR® platform IRVING ...
Benzinga.com

AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The $5.35 billion target ...
Yahoo Finance

Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Caris Life Sciences, Inc. stands tenth among them. Caris Life Sciences, Inc. (NASDAQ:CAI) is a ...